Furthermore, there is a supporting role for metabolic reprogramming in resistance to RAS pathway inhibition in BRAFV600E-mutated melanoma, in which the expression of glycolytic enzymes was restored upon the ectopic expression of NRASQ61K, and pharmacological inhibition of glycolysis resensitized these resistant cells to BRAF inhibitors19. The gene discussed is BRAF; the disease is melanoma.